Lipoprotein(a): What Lp(a) Means, Who Should Be Tested & Why It Matters

What to read next

• Start here for inherited cholesterol risk: Lipoprotein(a): The Inherited Cholesterol Particle Most People Have Never Heard Of.
• Compare the markers: Cholesterol Blood Tests: LDL-C vs ApoB vs Lp(a) vs hs-CRP.
• Build the LDL foundation: LDL Cholesterol: What the Number Means and Why It Matters.
• Build the nutrition foundation: Eating Well Without Overthinking It.
• Reduce nicotine risk: Quit Smoking: What the Evidence Says About Cigarettes, Vapes, and Nicotine Pouches.
• Read the evidence base: The Science Behind Vital8.
• Review the scoring appendix: Vital8 Methods and Scoring System.

The short answer

Lipoprotein(a), said "L-P-little-a," is a cholesterol-carrying particle in your blood whose level is set almost entirely by the genes you inherit. Having a high level is one of the most common inherited risk factors for heart attack, stroke, and a stiffening heart valve.[1][2]

About 1 in 5 people worldwide carry a high level, most of them without knowing it, because Lp(a) is not on a standard cholesterol panel and diet and exercise barely change it.[3][2] A single blood test, done once in a lifetime, usually tells you whether you carry it. And while no drug is yet approved specifically to lower Lp(a), several powerful medicines are now in final-stage trials.[1][4]

This is the story of a particle that hid from science for half a century, and why it may be the most important number you have never measured.

A particle discovered, then forgotten

In 1963, a Norwegian physician and geneticist named Kare Berg was studying the fatty proteins in human blood when he found something that did not belong. Mixed in with ordinary LDL, the "bad cholesterol," was a variant carrying an extra protein no one had catalogued. He called it lipoprotein(a).[5][6]

Berg was a geneticist first, and he quickly noticed something that would turn out to be the whole key: the amount of this particle a person carried seemed to run in families, fixed by inheritance rather than by how they lived. By 1974 he had linked it to coronary heart disease.[5] It was a remarkable early insight. And then, for the better part of two decades, the trail went cold.

The problem was technical, but it mattered enormously. Measuring Lp(a) accurately is genuinely difficult, and the early blood tests were crude. In the early 1990s, two carefully designed studies that followed people over time, the gold standard of evidence, used poorly calibrated assays on old frozen samples and found no link between Lp(a) and heart disease.[4]

To many, the case was closed: Berg had chased a red herring. The irony, discovered later, was almost poetic. When the samples from one of those very studies were re-tested with a proper assay, high Lp(a) turned out to be an excellent predictor of future heart disease after all.[4] The particle had not failed the test. The test had failed the particle.

The clue hidden in the gene

The revival began in 1987, when Richard Lawn, Angelo Scanu, and colleagues cloned and sequenced the gene that makes Lp(a), the gene now called LPA.[4][7] What they found was startling. The extra protein wrapped around this LDL-like particle, called apolipoprotein(a), had evolved from an almost unrelated gene: plasminogen, one of the body's central clot-dissolving proteins.[5]

That single fact reframed everything. Lp(a) was not just another cholesterol particle. It was a molecular hybrid, part cholesterol carrier and part impostor of the clot-busting machinery, which hinted that it might do damage in more than one way at once.[5][7] Scientists could now study the gene directly, and the gene does not lie.

The verdict: genetics closes the case

Here the story reaches its turning point. Because Lp(a) is more than 90% determined by the LPA gene, nature has effectively run a giant randomized experiment: people inherit high or low levels at conception, shuffled at random, long before lifestyle or other diseases could muddy the picture.[2][4] Studying this is called Mendelian randomization, and it is one of the most powerful tools in modern medicine for telling correlation from causation.

In 2009, two large genetic studies delivered the verdict.[5][4] People who had inherited gene variants for high Lp(a) had more coronary heart disease, not merely alongside it, but because of it. This was no longer a statistical association that could be explained away. It was cause and effect, written in the genome.

In a review I co-authored on Lp(a) risk factors, measurement, and emerging treatments, we described how large observational studies, genome-wide association studies, and Mendelian randomization studies together built the case linking Lp(a) to cardiovascular disease, even as those early, less sensitive assays had once obscured it.[3]

By 2013, the same genetic approach revealed that Lp(a) causes calcific narrowing of the aortic heart valve, a condition with no drug treatment at all, only surgery.[4] Lp(a) remains the single strongest genetic risk factor ever identified for that valve disease.[5]

What it actually does to you

Once scientists could see the particle clearly, its methods of harm came into focus. True to its two-faced gene, it works through several pathways at once.[7][8]

Like LDL, Lp(a) carries cholesterol into artery walls, seeding the plaques of atherosclerosis. But it does more. It is the blood's main carrier of oxidized phospholipids, inflammatory cargo that inflames the artery lining and recruits immune cells, accelerating plaque and making it more likely to rupture.[5]

And because its signature protein mimics the body's clot-dissolving plasminogen, it is thought to blunt the breakdown of clots, tipping the balance toward thrombosis.[7] Cholesterol deposition, inflammation, and clotting: three punches from one particle.

A large multi-ethnic US study shows how steadily cardiovascular risk climbs as Lp(a) rises across the population.[9]

The consequences are not evenly distributed across diseases, and honesty about that matters. The strongest links are to heart attack and aortic valve stenosis; the risk for peripheral artery disease and heart failure is real but smaller; and the connection to stroke and to overall death is weaker still.[4] For heart attack, people in the highest few percent of Lp(a) carry roughly two to three times the risk.[4]

Where the particle's reach ends

A trustworthy story includes the chapters that undercut the fear. Lp(a) is not behind everything.

The clearest example is dementia. Despite a plausible theory that a particle bad for arteries should be bad for the brain, the largest study to date, more than 539,000 people across three cohorts, found that Lp(a) levels were not associated with Alzheimer's disease or vascular dementia.[10] A 2026 real-world analysis of over 150,000 people reached the same conclusion: elevated Lp(a) was not linked to dementia or any of its major subtypes.[11]

Some studies have even, puzzlingly, found high Lp(a) associated with slightly slower cognitive decline.[12]

The kidney relationship also runs in a surprising direction: rather than Lp(a) damaging the kidneys, chronic kidney disease raises Lp(a) levels by impairing the particle's clearance, and elevated Lp(a) then adds to the already high heart risk in those patients.[13][2]

Knowing where a risk factor does not reach is part of what makes the rest of the case believable.

Why you cannot diet your way out of it

This is the hardest part of the story to accept, and the most important. Unlike LDL cholesterol, which responds to food, exercise, and weight loss, Lp(a) is stubbornly fixed by your genes. Smoking cessation, physical activity, fasting, and diet have minimal, if any, effect on it.[3][2] A person can do everything right and still carry a high level for life.

This is not a counsel of despair. It is a change of strategy. If you carry high Lp(a), the goal is not to chase the number with willpower but to slam shut every other door risk can walk through.

Guidelines are explicit that people with elevated Lp(a) should manage their other risk factors early and aggressively: LDL cholesterol, blood pressure, blood sugar, and smoking.[1][2] The payoff is concrete. Among people with high Lp(a), following a heart-healthy lifestyle has been associated with a 67% lower risk of cardiovascular disease.[1]

Your genes load the gun; the rest of your risk factors still pull the trigger.

The number to know, and when to check it

Because a single test can reveal a lifelong, silent, inherited risk, major guidelines now recommend that every adult have their Lp(a) measured at least once in their lifetime.[1][14] It does not require fasting, and because the level barely changes over a lifetime, once is usually enough.[1][2]

• A level of about 50 mg/dL, or 125 nmol/L, or higher is considered high. This is roughly the top 20% of the population and carries about a 40% higher relative risk of cardiovascular disease.[1][2]
• Around 80-100 mg/dL, the risk roughly doubles; around 180 mg/dL it is about four times higher. That is a risk on par with the inherited high-cholesterol disorder familial hypercholesterolemia.[1]
• Levels vary by ancestry. The highest levels are typically seen in people of African and South Asian descent, though the proportional increase in risk per unit is similar across groups.[1][2]

One of the most useful actions is cascade testing: if your level is high, your parents, siblings, and children each have roughly a 50% chance of carrying it too, and they deserve the chance to know.[1]

The chapter still being written: drugs that finally work

For all that we have learned, the current toolkit is frustrating. Statins, the workhorses of cholesterol care, do not lower Lp(a) and may nudge it up slightly.[2] PCSK9 inhibitors and inclisiran lower it modestly, by about 15-30%, but were not designed for it.[1] The only dedicated treatment, filtering the blood by apheresis, is effective but demanding.[2] Niacin lowers it but has not been shown to help and is not recommended for this purpose.[15]

But the story is turning, and fast. A new generation of medicines does something previous drugs could not: it switches off production of the particle at the source, silencing the LPA gene's message inside liver cells using RNA-based technology.[3][16] The results are dramatic: reductions of 80% to more than 90%.[4]

As of August 2026, several are in large, final-stage trials designed to prove the last remaining question: that lowering Lp(a) actually prevents heart attacks and strokes, not just the number on a lab report.[4][17]

• Pelacarsen is a monthly injection in a phase 3 outcomes trial of more than 8,000 people with heart disease and high Lp(a).[4]
• Olpasiran and lepodisiran are injections needed only a few times a year, also in phase 3.[4][17]
• Muvalaplin is notably a daily pill rather than an injection, at an earlier stage.[4]

These therapies serve a double purpose: they may finally give doctors a way to treat high Lp(a), and by doing so they will settle, once and for all, whether lowering the particle lowers risk.[3] If they succeed, a risk factor that hid from science for fifty years and has been untreatable for sixty could become, at last, something we can fix.

How this fits into Vital8

In Vital8, Lp(a) is not one of the original Life's Essential 8 domains. It sits in the optional biomarker layer because it is a genetic risk amplifier rather than a behavior target. That distinction matters: the point is not to punish someone for inherited risk, but to identify people who may need earlier and more aggressive control of modifiable risk factors.

That means Lp(a) belongs next to the Control Cholesterol domain, the LDL guide, and the Vital8 methods appendix, where the biomarker adjustment logic is documented.

Frequently asked questions

What is a normal Lp(a) level? Below about 30 mg/dL, or 75 nmol/L, is generally considered low risk; 50 mg/dL, or 125 nmol/L, or above is high; in between is intermediate. Levels are usually stable for life, so a single test is typically enough.[15]

Should I get my Lp(a) tested? Major guidelines recommend that every adult have Lp(a) measured at least once. It is especially important if you have a personal or family history of early heart disease, high cholesterol, or a known family history of high Lp(a).[1][14]

Can diet or exercise lower Lp(a)? No, or only trivially. Lp(a) is set by your genes and does not meaningfully respond to lifestyle. That is exactly why controlling your other risk factors matters so much if your level is high.[3][2]

If Lp(a) is genetic and untreatable, why bother knowing my level? Because the knowledge changes what you do about everything else, prompting earlier and more aggressive control of cholesterol, blood pressure, and other risks, and it lets your relatives get tested. Effective medicines targeting Lp(a) directly are also now close.[3][1]

Does high Lp(a) cause dementia? The best current evidence says no. Large studies have not found a link between Lp(a) and Alzheimer's disease or vascular dementia.[10][11]

The moral of the story

Lp(a) is a lesson in scientific humility and persistence. A particle found in 1963, dismissed in the 1990s because our instruments were too blunt to see it clearly, and finally convicted by the genome in 2009, was real all along.

Today it is one of the most common inherited risk factors we know of, and one of the last major ones we still cannot treat. That last part is about to change. Knowing your number now means you and your family can act on everything else in the meantime, and be first in line when the treatments arrive.[3][4]

Related reading

• Vital8 Control Cholesterol
• Life's Essential 8 and the Vital8 framework
• Check your Vital8 score
• LDL Cholesterol: What the Number Means and Why It Matters
• Cholesterol Blood Tests: LDL-C vs ApoB vs Lp(a) vs hs-CRP
• ApoB Test: What It Measures, Why It Matters, and How to Lower It
• Eating Well Without Overthinking It
• Quit Smoking: What the Evidence Says About Cigarettes, Vapes, and Nicotine Pouches
• The Science Behind Vital8
• Vital8 Methods and Scoring System

References

1. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Writing Committee Members, Blumenthal RS, Morris PB, et al. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423.
2. Lipoprotein(a). Mora S, Kronenberg F. JAMA. 2025;333(21):1918-1919. doi:10.1001/jama.2025.2373.
3. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Cardiology in Review. 2025;33(4):352-358. doi:10.1097/CRD.0000000000000667.
4. Lipoprotein(a) and Cardiovascular Disease. Nordestgaard BG, Langsted A. Lancet. 2024;404(10459):1255-1264. doi:10.1016/S0140-6736(24)01308-4.
5. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. doi:10.1161/ATV.0000000000000147.
6. Lipoprotein(a) and its Significance in Cardiovascular Disease. Duarte Lau F, Giugliano RP. JAMA Cardiology. 2022;7(7):760-769. doi:10.1001/jamacardio.2022.0987.
7. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Vinci P, Di Girolamo FG, Panizon E, et al. International Journal of Environmental Research and Public Health. 2023;20(18):6721. doi:10.3390/ijerph20186721.
8. The Residual Risk Odyssey: From LDL to Lp(a). Rosenson RS, Goonewardena SN. Journal of the American College of Cardiology. 2021;78(5):434-436. doi:10.1016/j.jacc.2021.04.103.
9. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. Wong ND, Fan W, Hu X, et al. Journal of the American College of Cardiology. 2024;83(16):1511-1525. doi:10.1016/j.jacc.2024.02.031.
10. Lipoprotein(a) and Risk of Dementia: Findings From Three Cohort Studies. Thomas PE, Vedel-Krogh S, Nielsen SF, et al. European Heart Journal. 2025. doi:10.1093/eurheartj/ehaf465.
11. Lipoprotein(a) and Risk of Dementia: A Propensity Score-Matched Real-World Analysis From a Global Federated Research Network. Rossi M, Tartaglia E, Askarinejad A, et al. European Journal of Internal Medicine. 2026;150:106984. doi:10.1016/j.ejim.2026.106984.
12. ApoB, Small-Dense LDL-C, Lp(a), LpPLA2 Activity, and Cognitive Change. Pokharel Y, Mouhanna F, Nambi V, et al. Neurology. 2019;92(22):e2580-e2593. doi:10.1212/WNL.0000000000007574.
13. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Tsimikas S, Fazio S, Ferdinand KC, et al. Journal of the American College of Cardiology. 2018;71(2):177-192. doi:10.1016/j.jacc.2017.11.014.
14. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Mach F, Koskinas KC, Roeters van Lennep JE, et al. European Heart Journal. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190.
15. A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice. Koschinsky ML, Bajaj A, Boffa MB, et al. Journal of Clinical Lipidology. 2024;18(3):e308-e319. doi:10.1016/j.jacl.2024.03.001.
16. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3. Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Journal of the American College of Cardiology. 2023;81(16):1633-1645. doi:10.1016/j.jacc.2023.02.033.
17. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). Nissen SE, Linnebjerg H, Shen X, et al. JAMA. 2023;330(21):2075-2083. doi:10.1001/jama.2023.21835.

This guide is part of the MendelMD preventive cardiology library. Explore cholesterol and lipid guides and the LDL reduction calculator. Vital8 is our broader framework for cardiovascular health.